Spain OKs Bentley cancer drug

NH Business Review Staff,

Bentley Pharmaceuticals has won its first approval to market a genetic cancer drug in Spain, a $65 million market, the company announced Wednesday.

The Exeter-based generic pharmaceuticals company, whose major subsidiary and marketing is in Europe, particularly Spain, said the drug – bicalutamide – is the equivalent of Casodex, which prevents the growth of prostate cancer by blocking the effects of androgens on the cancer cells. The product is orally administered as a 50 mg, tablet, a market that has grown 12 percent in the last months.

Before launching bicalutamide, the company must apply for product pricing and build an inventory – BOB SANDERS

Categories: News

More news from NHBR:

Nhopinions
Opinion

(Opinion) Novus Public Affairs’ 30-year anniversary: Paul Young’s meaningful mark on NH

For nearly six decades, Paul Young has been a constant, if often understated, presence in public and government affairs, both in New Hampshire and beyond. Since founding Novus Public Affairs in 1996, Young has helped shape how businesses, nonprofits and political leaders communicate and connect with the world around them, leaving a mark on the state that is hard to measure but easy to feel.